Patents by Inventor Sandra Ann Filla
Sandra Ann Filla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8202873Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently —C(H)? or —N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R1-4 are as defined herein.Type: GrantFiled: May 7, 2008Date of Patent: June 19, 2012Assignee: Eli Lilly and CompanyInventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
-
Patent number: 8173821Abstract: A serotonin and norepinephrine reuptake inhibitor of the formula: its uses, and methods for its preparation are described.Type: GrantFiled: April 6, 2010Date of Patent: May 8, 2012Assignee: Eli Lilly and CompanyInventors: Nicolas Jacques Francois Dreyfus, Sandra Ann Filla, Anette Margareta Johansson, Thierry J. Masquelin, Jikesh Arvind Shah, Eric George Tromiczak, Magnus Wilhelm Walter
-
Patent number: 8048884Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is —C(H)? or —N?; m is 0, 1 or 2; R1 is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyridyl, or thienyl; R2 is hydrogen or methyl; and R3 and R4 are as defined herein.Type: GrantFiled: August 19, 2008Date of Patent: November 1, 2011Assignee: Eli Lilly and CompanyInventors: Michael Philip Cohen, Sarah Lynne Hellman, Sean Patrick Hollinshead, Sandra Ann Filla, Michael Wade Tidwell
-
Patent number: 7910588Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is —C(H)? or —N? and R1-7 are as defined herein.Type: GrantFiled: September 30, 2008Date of Patent: March 22, 2011Assignee: Eli Lilly and CompanyInventors: Valentina O Badescu, Sandra Ann Filla, Peter Thaddeus Gallagher, Maria Ann Whatton
-
Publication number: 20110034511Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein X is C(R3c)? or N?; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b and, when X is —C(R3c)?, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided that when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively.Type: ApplicationFiled: September 28, 2010Publication date: February 10, 2011Applicant: Eli Lilly and CompanyInventors: Maria-Jesus Blanco-Pillado, Michael Philip Cohen, Sandra Ann Filla, Kevin John Hudziak, Daniel Timothy Kohlman, Dana Rae Benesh, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang, Brian Michael Mathes
-
Publication number: 20100261762Abstract: A serotonin and norepinephrine reuptake inhibitor of the formula: its uses, and methods for its preparation are described.Type: ApplicationFiled: April 6, 2010Publication date: October 14, 2010Applicant: Eli Lilly and CompanyInventors: Nicolas Jacques Francois DREYFUS, Sandra Ann FILLA, Anette Margareta JOHANSSON, Thierry J. MASQUELIN, Jikesh Arvind SHAH, Eric George TROMICZAK, Magnus Wilhelm WALTER
-
Publication number: 20100197700Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is —C(H)? or —N? and R1-7 are as defined herein.Type: ApplicationFiled: September 30, 2008Publication date: August 5, 2010Inventors: Valentina O Badescu, Sandra Ann Filla, Peter Thaddeus Gallagher, Maria Ann Whatton
-
Publication number: 20100120785Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)? or N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R14 are as defined herein.Type: ApplicationFiled: May 7, 2008Publication date: May 13, 2010Applicant: ELI LILLY AND COMPANYInventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
-
Publication number: 20100075976Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is —C(H)? or —N?; m is 0, 1 or 2; R1 is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyridyl, or thienyl; R2 is hydrogen or methyl; and R3 and R4 are as defined herein.Type: ApplicationFiled: August 19, 2008Publication date: March 25, 2010Inventors: Michael Philip Cohen, Sarah Lynne Hellman, Sean Patrick Hollinshead, Sandra Ann Filla, Michael Wade Tidwell
-
Patent number: 7608629Abstract: The present invention relates to compounds of formula 1: and pharmaceutically acceptable acid addition sails thereof. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or preverition of migraine in mammals, particularly humans.Type: GrantFiled: April 14, 2004Date of Patent: October 27, 2009Assignee: Eli Lilly and CompanyInventors: Maria-Jesus Blanco-Pillado, Dana Rae Benesh, Sandra Ann Filla, Kevin John Hudziak, Brian Michael Mathes, Daniel Timothy Kohlman, Bai-Ping Ying, Deyi Zhang, Yao-Chang Xu
-
Publication number: 20090099210Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.Type: ApplicationFiled: December 22, 2008Publication date: April 16, 2009Applicant: ASTRAZENECA ABInventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Ann Filla, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
-
Patent number: 7498333Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.Type: GrantFiled: August 18, 2005Date of Patent: March 3, 2009Assignee: AstraZeneca ABInventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Ann Filla, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
-
Patent number: 7417064Abstract: There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, —CF3, —CN and —CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, nitro, acetyl, —CF3, —SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenylType: GrantFiled: October 24, 2003Date of Patent: August 26, 2008Assignee: Eli Lilly and CompanyInventors: Serge Louis Boulet, Sandra Ann Filla, Peter Thaddeus Gallagher, Kevin John Hudziak, Anette Margareta Johansson, Rushad E. Karanjawala, John Joseph Masters, Victor Giulio Matassa, Brian Michael Mathes, Richard Edmund Rathmell, Maria Ann Whatton, Chad Nolan Wolfe
-
Patent number: 7410996Abstract: There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, —CF3, —CN and —CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0,Type: GrantFiled: October 24, 2003Date of Patent: August 12, 2008Assignee: Eli Lilly and CompanyInventors: Serge Louis Boulet, Sandra Ann Filla, Peter Thaddeus Gallagher, Kevin John Hudziak, Anette Margareta Johansson, Rushad E. Karanjawala, John Joseph Masters, Victor Giulio Matassa, Brian Michael Mathes, Richard Edmund Rathmell, Maria Ann Whatton, Chad Nolan Wolfe
-
Patent number: 7410982Abstract: There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from —O— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl —S(O)n— where n is 0, 1 or 2, —CF3, —CN and —CONH2; Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, and thienopyridyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n— where n is 0, 1 or 2, nitro acetyl, —CF3, —SCF3 aType: GrantFiled: October 24, 2003Date of Patent: August 12, 2008Assignee: Eli Lilly and CompanyInventors: Serge Louis Boulet, Sandra Ann Filla, Peter Thaddeus Gallagher, Kevin John Hudziak, Anette Margareta Johansson, Rushad E. Karanjawala, John Joseph Masters, Brian Michael Mathes, Richard Edmund Rathmell, Maria Ann (nee Fagan) Whatton, Victor Matassa, Chad Nolan Wolfe
-
Patent number: 7291632Abstract: The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c? or N?; R1 is C2–C6 alkyl, substituted C2–C6 alkyl, C3–C7 cycloalkyl, substituted C3–C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1–C3 n-alkyl, C3–C6 cycloalkyl-C1–C3 alkyl, or a group of formula II (II) provided that when R1 is C2–C6 alkyl or substituted C2–C6 alkyl, R2 is hydrogen or methyl; R3a, R3b, and, when X is C(R3c)?, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1–C3 alkyl; R5 is hydrogen, C1–C3 alkyl, or C3–C6 cycloalkylcarbonyl, provided that when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1–C6 alkyl; and n is an integer from 1 to 6 inclusively.Type: GrantFiled: September 3, 2004Date of Patent: November 6, 2007Assignee: Eli Lilly and CompanyInventors: Maria-Jesus Blanco-Pillado, Michael Philip Cohen, Sandra Ann Filla, Kevin John Hudziak, Daniel Timothy Kohlman, Dana Rae Benesh, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang, Brian Michael Mathes
-
Patent number: 7230011Abstract: The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.Type: GrantFiled: January 17, 2002Date of Patent: June 12, 2007Assignee: Eli Lilly and CompanyInventors: Sandra Ann Filla, Michael Edward Flaugh, James Ronald Gillig, Lawrence Joseph Heinz, Joseph Herman Krushinski, Jr., Bin Liu, Marta Maria Pineiro-Nunez, John Mehnert Schaus, John Stanley Ward
-
Patent number: 7157582Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.Type: GrantFiled: January 11, 2005Date of Patent: January 2, 2007Assignee: Eli Lilly and CompanyInventors: Sandra Ann Filla, Paul Leslie Ornstein
-
Patent number: 6953805Abstract: The present invention provides novel compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II in combination with a suitable carrier, diluent, or excipient, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.Type: GrantFiled: December 20, 2001Date of Patent: October 11, 2005Assignee: Eli Lilly and CompanyInventors: Sandra Ann Filla, Kevin John Hudziak, Brian Michael Mathes, Paul Leslie Ornstein
-
Patent number: 6855823Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.Type: GrantFiled: April 9, 2004Date of Patent: February 15, 2005Assignee: Eli Lilly and CompanyInventors: Sandra Ann Filla, Paul Leslie Ornstein